Marex Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Marex Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-344,500	Closed	-$1.74M	–	985
2025 Q2	$1.74M	Buy	+344,500	New	+$1.69M	0.02%	239

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Marex Group's RXRX Position: Q2 2026 in Review

Marex Group sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 32,788 shares — an estimated $101K sold.

Marex Group first reported a position in RXRX in Q2 2025 and held it in 2 quarters. The position peaked at $1.8M in Q2 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Marex Group reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Marex Group sold 32,788 Recursion Pharmaceuticals shares in Q2 2026, an estimated $101K.
Marex Group first reported a position in Recursion Pharmaceuticals in Q2 2025 and held it in 2 quarters.
Marex Group's Recursion Pharmaceuticals position peaked at $1.8M in Q2 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.